2019 Participants

Almirall is a leading global pharmaceutical company, focused in medical dermatology and headquartered in Barcelona. Our strong commitment is to improve patients’ quality life while caring and listening to them. We work to offer innovative and differentiated medicines for skin conditions with high unmet need. We cover the whole of the drug value chain through an expert R&D organisation as well as key partnerships.

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Our significant investment in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions from target to clinic. For additional information, please go to www.evotec.com and follow us on Twitter @Evotec.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed over 100,000 people worldwide.

Alongside the broad internal pipeline, external innovation has always been a critical component of the Roche research and development strategy. Only in 2020, Roche entered into 92 new partnerships and is managing over 220 ongoing alliances worldwide.